The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa

Thrombosis and Haemostasis

Volumn 108, Issue 2, 2012, Pages 266-276

  Peraramelli, Sameera ^a   Suylen, Dennis P L ^a   Rosing, Jan ^a   Hackeng, Tilman M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anticoagulant; Factor Xa; Protein S; TFPI

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CALCIUM ION; EDETIC ACID; KUNITZ DOMAIN PROTEIN; LEUKOCYTE ELASTASE; PEPTIDES AND PROTEINS; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION;

AMINO ACID SEQUENCE; ANIMALS; ANTICOAGULANTS; CALCIUM; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FACTOR XA; HUMANS; IONS; KINETICS; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; OXYGEN; PEPTIDES; PROTEIN FOLDING; PROTEIN S; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84864330024     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-12-0902     Document Type: Article

References (28)

1. Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67: 3-12.
2. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
3. Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
4. Nemerson Y. The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 1966; 5: 601-608.
5. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264.
6. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitztype inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520.
7. Broze GJ, Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
8. van 't Veer C, Golden NJ, Kalafatis M, et al. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 1997; 272: 7983-7994.
9. Wun TC, Kretzmer KK, Girard TJ, et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-6004.
10. Wesselschmidt R, Likert K, Huang Z, et al. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661-669.
11. Ndonwi M, Tuley EA, Broze GJ, Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010; 116: 1344-1351.
12. Hackeng TM, Sere KM, Tans G, et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103: 3106-3111.
13. Broze GJ, Jr., Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343.
14. Broze GJ, Jr., Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546.
15. Huang ZF, Wun TC, Broze GJ, Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-26955.
16. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988; 61: 201-301.
17. Petersen LC, Bjorn SE, Olsen OH, et al. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem 1996; 235: 310-316.
18. Higuchi DA, Wun TC, Likert KM, et al. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-1719.
19. Sere KM, Rosing J, Hackeng TM. Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance. Blood 2004; 104: 3624-3630.
20. Diaz-Collier JA, Palmier MO, Kretzmer KK, et al. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 1994; 71: 339-346.
21. Petersen JG, Meyn G, Rasmussen JS, et al. Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae. J Biol Chem 1993; 268: 13344-13351.
22. Esnouf MP, Lloyd PH, Jesty J. A method for the simultaneous isolation of factor X and prothrombin from bovine plasma. Biochem J 1973; 131: 781-789.
23. Schnolzer M, Alewood P, Jones A, et al. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int J Pept Protein Res 1992; 40: 180-193.
24. Hackeng TM, Griffin JH, Dawson PE. Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci USA 1999; 96: 10068-10073.
25. Girard TJ, Broze GJ, Jr. Tissue factor pathway inhibitor. Methods Enzymol 1993; 222: 195-209.
26. Dawson PE, Muir TW, Clark-Lewis I, et al. Synthesis of proteins by native chemical ligation. Science 1994; 266: 776-779.
27. Ndonwi M, Tuley EA, Broze GJ, Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010; 116: 1344-1351.
28. Lindhout T, Franssen J, Willems G. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-915.